FFO
LSTA icon

Fortitude Family Office’s Lisata Therapeutics LSTA Stock Holding History

Fortitude Family Office’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3 Hold
1
– – ﹤0.01% 2265
2026
Q1 		$5 Hold
1
– – ﹤0.01% 1882
2025
Q4 		$2 Buy
+1
New +$2 ﹤0.01% 1916

Other funds holding LSTA

DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
FCMT
Founders Capital Management (Texas) Houston, Texas $231M AUM 61.68% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Fortitude Family Office's LSTA Position: Q2 2026 in Review

Fortitude Family Office held its Lisata Therapeutics (LSTA) position steady in Q2 2026 at 1 share worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #2265.

Fortitude Family Office first reported a position in LSTA in Q4 2025 and has held it in 3 quarters since. The position peaked at $5 in Q1 2026. 5 funds tracked by Wall St. Rank hold LSTA as of Q2 2026.

  • Fortitude Family Office held 1 share of Lisata Therapeutics worth $3 as of Q2 2026.
  • Fortitude Family Office left its Lisata Therapeutics share count unchanged in Q2 2026.
  • Lisata Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2265 holding.
  • Fortitude Family Office first reported a position in Lisata Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Fortitude Family Office's Lisata Therapeutics position peaked at $5 in Q1 2026.
  • 5 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.